Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.

Kim DaoYimin LuCody J PeerWilliam D FiggRaphael StadelmannMichel BurnierThierry BuclinSebastien Kissling

Published in: Cancer chemotherapy and pharmacology (2016)

Lenalidomide doses of 5 mg b.i.d. led to high exposure in a patient with renal failure undergoing high cut-off dialysis. Yet, the dosage of 5 mg q.d. recommended in conventional dialysis would probably be adequate in such patients.

Keyphrases

end stage renal disease
chronic kidney disease
multiple myeloma
peritoneal dialysis
newly diagnosed
case report
ejection fraction
stem cell transplantation
prognostic factors
chronic lymphocytic leukemia